Introduction
============

Lung cancer is a common clinical malignancy.[@b1-tcrm-14-2213]--[@b3-tcrm-14-2213] In clinical oncology, lung cancer is classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer, based on the biological characteristics and treatment methods. NSCLC accounts for approximately 85%--90% of lung cancer cases.[@b4-tcrm-14-2213],[@b5-tcrm-14-2213] Surgery is the mainstay treatment for patients with NSCLC.[@b6-tcrm-14-2213]--[@b8-tcrm-14-2213] Since the first case of video-assisted thoracic surgery lobectomy (VATS) treatment for NSCLC in 1992,[@b9-tcrm-14-2213] studies have shown that compared with open surgery, VATS treatment of early stage NSCLC resulted in less blood loss, faster postoperative recovery, less trauma, similar or reduced postoperative complications, and similar long-term outcomes.[@b10-tcrm-14-2213]--[@b22-tcrm-14-2213] VATS has gradually been applied in the treatment of locally advanced NSCLC (LA-NSCLC), due to accumulation of experience and continuous improvement of surgical instruments.[@b23-tcrm-14-2213]--[@b34-tcrm-14-2213] As life expectancy per capita increases, the occurrence of NSCLC in elderly patients has shown an increasing trend. Studies demonstrated that VATS treatment in elderly patients with early stage NSCLC can result in outcomes similar to those in nonelderly patients.[@b35-tcrm-14-2213]--[@b37-tcrm-14-2213] However, according to our literature search, to date, there are no published reports in English on the treatment of LA-NSCLC with VATS in elderly patients. This study was aimed to investigate the clinical value of VATS for the treatment of LA-NSCLC in elderly patients, by comparing the short- and long-term outcomes of VATS in elderly and middle-aged patients with LA-NSCLC.

Patients and methods
====================

This retrospective study complied with the tenets of the Declaration of Helsinki and was approved by the local ethics committees. The need for informed consent from all patients was waived as the study was retrospective.

From January 2012 to January 2018, a total of 106 patients with LA-NSCLC underwent VATS at our hospital. Patients who fulfilled the following inclusion criteria were enrolled in this study: 1) clinical stage of IIA--IIIA; 2) complete clinical and follow-up data available; 3) surgical approach used was VATS, including conversion to open thoracotomy; and 4) diagnosis of NSCLC. Exclusion criteria were: 1) diagnosis of SCLC; 2) patients who underwent bilobectomy or pneumonectomy; 3) patients requiring multivisceral resections due to local tumor invasion; and 4) presence of other malignant tumors. After screening, a total of 83 patients were included in the study to compare the short- and long-term outcomes (including cancer recurrence, disease-free, and overall survival) between the ≥70 years (37 cases) and 55--69 years (46 cases) groups. Preoperative chest computed tomography (CT), cardiopulmonary function testing, brain CT/magnetic resonance imaging, abdominal CT/ultrasound, bone scan, and laboratory examinations were conducted to determine clinical staging and exclude distant metastases. When mediastinal lymph node enlargement was demonstrated on chest CT, endobronchial ultrasound transbronchial needle aspiration or mediastinoscopic biopsy was performed first. Positron emission tomography/CT was not mandatory in every patient. Complete VATS without hand-assisted technique was used in this study. VATS was performed via a 4-cm utility incision at the anterior axillary line, at the fourth or fifth intercostal space, without rib spreading. A port at the eighth or seventh intercostal space, at the posterior axillary line, was used for camera visualization, and a posterior port was used for lung retraction and stapler insertion. Details of specific operations can be found in a previous literature report.[@b29-tcrm-14-2213]

The Clavien--Dindo criteria were used to classify the severity of postoperative 30-day complications. Minor complications were defined as Grades I--II and major complications were defined as Grades III--V.[@b38-tcrm-14-2213] Postoperative 30-day mortality was defined as any death from oncological or nononcological causes within 30 days after surgery.

Patients with pathological stage greater than or equal to stage II were recommended to receive postoperative adjuvant chemotherapy, if there was no contraindication to chemotherapy.[@b39-tcrm-14-2213]

The permanent home address and contact information of the patients were registered at hospital discharge. Follow-up was conducted by interviews in the outpatient settings and/or through telephone interviews, home visits, or communication with family members, as well as by other means. The patients were followed up once every 3 months in the first postoperative year, once every 4 months in the second postoperative year, once every 6 months in the third postoperative year, and once a year thereafter.[@b40-tcrm-14-2213] The follow-up appointments included physical examination, routine laboratory tests, and brain/chest/abdominal CT scans. Patients with suspected bone metastases underwent bone scanning.[@b40-tcrm-14-2213]

Patients with suspected tumor recurrence were referred to our hospital. Locoregional recurrence was defined if it occurred in 1) the bronchial stump or cut end of the lung parenchyma, 2) the ipsilateral pleura and/or chest wall, or 3) the ipsilateral hilar and/or mediastinal lymph nodes.[@b40-tcrm-14-2213] Recurrence was defined as distant if it occurred in a separate lobe of the ipsilateral lung, contralateral thorax, supraclavicular lymph nodes, or in a distant organ. If distant recurrences were identified by systemic survey within a month after the detection of locoregional recurrence, these were defined as concurrent distant and locoregional recurrence.[@b40-tcrm-14-2213] Overall survival was calculated from the date of radical resection to the last follow-up visit or death from any cause. Disease-free survival was assessed from the date of radical resection until the date of cancer recurrence or death from any cause.[@b40-tcrm-14-2213] The latest follow-up included in this study was in March 2018.

Statistics
----------

Categorical variables are presented as frequencies and percentages, and continuous variables are presented as median values with range. Statistical analyses were performed with the chi-squared test, Fisher's exact test, and Mann--Whitney *U* test for categorical and continuous variables, respectively. Overall survival and disease-free survival rates were estimated by the Kaplan--Meier method, with differences in survival between groups compared by the log-rank test. The Cox proportional hazard model was used to identify significant predictive factors for patient survival outcomes. Results are expressed as ORs with 95% CIs. All analyses were performed using the Statistical Package for Social Sciences 13.0 for Microsoft Windows version. *P*\<0.05 was considered to be statistically significant.

Results
=======

Patients who were ≥70 years of age had higher American Society of Anesthesiologists scores than the 55--69 years patients ([Table 1](#t1-tcrm-14-2213){ref-type="table"}). There was no significant difference between the two groups in gender, simplified comorbidity score (SCS), tumor site, neoadjuvant chemotherapy, and tumor/node/metastasis staging ([Table 1](#t1-tcrm-14-2213){ref-type="table"}).

There was no significant difference between the elderly group and the middle-aged group in terms of length of surgery, intraoperative blood loss, conversion to thoracotomy, drainage time, and postoperative hospitalization time ([Table 2](#t2-tcrm-14-2213){ref-type="table"}).

The postoperative 30-day complications in the elderly patients were similar to those in the middle-aged group. The most common complication was prolonged air leakage. The incidence of postoperative 30-day major complications was similar in both groups. No mortality occurred intraoperatively or within 30 days postoperatively ([Table 2](#t2-tcrm-14-2213){ref-type="table"}). There were no significant differences in the pathological data between the two groups ([Table 3](#t3-tcrm-14-2213){ref-type="table"}).

Twenty-nine and 36 patients in the ≥70 years and 55--69 years groups, respectively, received at least one cycle of adjuvant chemotherapy. There was no significant difference in compliance with adjuvant chemotherapy between the two groups ([Table 4](#t4-tcrm-14-2213){ref-type="table"}).

The median follow-up periods for the ≥70 years and 55--69 years groups were 35 and 38 months, respectively, and no significant difference was observed. During the follow-up period, 9 and 11 patients died in the ≥70 years and 55--69 years groups, respectively. Among the nine deaths in the ≥70 years group, eight were due to cancer recurrence, and one was due to stroke; among the eleven deaths in the 55--69 years group, ten were due to cancer recurrence and one was due to noncancer factors ([Table 5](#t5-tcrm-14-2213){ref-type="table"}). The 5-year overall survival rate in the ≥70 years and 55--69 years groups was 54% and 59%, respectively; this difference was not statistically significant ([Figure 1](#f1-tcrm-14-2213){ref-type="fig"}, *P*=0.570). Multivariate analysis showed that the T stage, N stage, and SCS were independent predictors of overall patient survival ([Table 6](#t6-tcrm-14-2213){ref-type="table"}).

During the follow-up period, cancer recurrence was observed in 29 patients and 32 patients in the ≥70 years and 55--69 years groups, respectively. There was no significant difference between the two groups in terms of cancer recurrence rate and recurrence site. The 5-year disease-free survival rate in the ≥70 years and 55--69 years groups was 41% and 43%, respectively; this difference was not significant ([Figure 2](#f2-tcrm-14-2213){ref-type="fig"}, 0.831). Multivariate analysis showed that T stage, N stage, and SCS were independent predictors of disease-free survival rate ([Table 7](#t7-tcrm-14-2213){ref-type="table"}).

Discussion
==========

Compared with that of early stage NSCLC, treatment of LA-NSCLC with VATS is more difficult. The first case of VATS treatment for LA-NSCLC was reported by Petersen et al of Duke University Medical Center (USA) in 2006.[@b34-tcrm-14-2213] In their study,[@b34-tcrm-14-2213] Petersen et al performed VATS treatment on 12 patients with LA-NSCLC, and 1 patient was converted to thoracotomy. Compared with thoracotomy, VATS has the advantages of shorter drainage time and shorter hospitalization time. There was no significant difference in postoperative complications, postoperative mortality, and prognosis, indicating that VATS can result in outcomes similar to those of open surgery when treating LA-NSCLC.[@b34-tcrm-14-2213] Subsequently, numerous studies have reported similar conclusions.[@b23-tcrm-14-2213]--[@b34-tcrm-14-2213] In the present study, the short- and long-term outcomes of elderly patients were similar to previous reports, indicating that VATS is safe and feasible for the treatment of LA-NSCLC.

Potential treatment methods for LA-NSCLC in elderly patients include radiotherapy, radiofrequency ablation, and surgery.[@b41-tcrm-14-2213] Studies have shown that the survival rate of elderly patients with LA-NSCLC who underwent surgical treatment is better than that of patients who underwent nonsurgical treatment.[@b42-tcrm-14-2213] The clinical guidelines issued by the European Society for Medical Oncology also recommend surgical treatment to improve survival rate in elderly patients with LA-NSCLC with indications for surgery.[@b43-tcrm-14-2213] Based on our search in available databases such as PubMed, Embase, and Chemical Abstracts, to the best of our knowledge, VATS has not been reported in the English language for the treatment of LA-NSCLC in elderly patients. This study was the first to demonstrate that elderly patients with LA-NSCLC treated by VATS can show similar long-term outcomes compared to middle-aged patients.

Elderly patients with NSCLC often present with comorbidities. Comorbidity refers to diseases that exist at the time of diagnosis of NSCLC, such as respiratory diseases and cardiovascular diseases. The impact of comorbidities on elderly patients with cancer has received increasing attention. Studies have shown that the presence of comorbidities, rather than cancer itself, is the main reason for the lower survival rate in elderly patients with NSCLC compared with nonelderly patients, making it difficult for elderly patients to tolerate surgery, radiotherapy, and chemotherapy.[@b44-tcrm-14-2213] The Charlson Comorbidity Index (CCI), designed by Charlson et al in 1987, includes 19 common comorbidities, and is the most commonly used method to evaluate cancer complications in Western countries.[@b45-tcrm-14-2213] It has been applied in clinical studies evaluating head and neck tumors, urinary tract cancer, and breast cancer. Most studies have shown that a higher CCI score is associated with a poorer prognosis.[@b45-tcrm-14-2213]--[@b47-tcrm-14-2213] However, when CCI is applied in NSCLC, studies have shown that it cannot be used to assess patient prognosis.[@b48-tcrm-14-2213],[@b49-tcrm-14-2213] The reason for this is that CCI was derived from the study of comorbidities in patients with breast cancer. The comorbidities that affect breast cancer prognosis are very different from those of NSCLC, even though 19 common comorbidities are involved. Some comorbidities that may affect the prognosis of lung cancer, such as smoking, were not included in the score. The SCS was derived from the study of the prognostic impact of comorbidities on NSCLC, and it classified comorbidities into seven categories.[@b50-tcrm-14-2213] In the SCS score, smoking accounts for a high proportion (7 points). Smoking is the leading cause of the increased incidence and mortality rate of lung cancer. A study by Tomohiro Haruki et al showed that patients with high SCS scores had poorer VATS outcomes than those with low SCS scores.[@b51-tcrm-14-2213] In the present study, SCS was identified as an independent predictor of patient survival.

Clinical trials have shown that adjuvant chemotherapy can reduce the recurrence rate and improve the survival rate of patients with NSCLC.[@b41-tcrm-14-2213] Clinical guidelines recommend adjuvant chemotherapy for patients with stage II and III NSCLC.[@b41-tcrm-14-2213] Adjuvant chemotherapy plays a very important role in the prognosis of patients with NSCLC.[@b41-tcrm-14-2213] Studies have shown that the earlier the initiation of adjuvant chemotherapy, the higher will be the tolerability and the better will be the prognosis of the patients.[@b39-tcrm-14-2213]--[@b41-tcrm-14-2213] To our knowledge, there is no report on the effects of VATS treatment on postoperative adjuvant chemotherapy in elderly patients with NSCLC. Our study showed for the first time that elderly patients can achieve early initiation time and tolerability for postoperative adjuvant chemotherapy compared with middle-aged patients. In this study, the survival rate of elderly and middle-aged patients was similar, which may be due to improved tolerability of the procedure among elderly patients.

Conversion thoracotomy is inevitable in VATS. It has been reported that the thoracotomy conversion rate was 0%--23% when VATS was used to treat LA-NSCLC, depending on case selection and surgeon experience.[@b23-tcrm-14-2213]--[@b34-tcrm-14-2213] In our study, we found a conversion rate of 7% and 6% in elderly and middle-aged patients, respectively, which is similar to that reported in previous studies.[@b23-tcrm-14-2213]--[@b34-tcrm-14-2213] The vast majority of conversion thoracotomy cases in this study were due to uncontrolled bleeding, followed by tissue adhesion. To date, there is no report in the English language on the VATS conversion rate in elderly patients with LA-NSCLC. Our study showed for the first time that when VATS is used in the treatment of elderly patients with LA-NSCLC, the conversion rate is similar to that of middle-aged patients.

In this study, the long-term outcomes including cancer recurrence, overall survival, and disease-free survival were similar between groups. Previous reports on VATS treatment of patients with LA-NSCLC reported a cancer recurrence rate of 10%--30%, a 5-year overall survival rate of 50%--60%, and a 5-year disease-free survival rate of 30%--50%.[@b23-tcrm-14-2213]--[@b34-tcrm-14-2213] The results of this study are similar to previous findings. To our knowledge, no study has reported the 5-year overall survival and 5-year disease-free survival rates in elderly patients with LA-NSCLC treated with VATS. This study demonstrates, for the first time, that elderly patients with LA-NSCLC treated with VATS can achieve similar long-term outcomes as those of nonelderly patients.

Concurrent chemoradiotherapy is a common therapeutic method for NSCLC patients with no surgical indications. However, there is debate on whether concurrent chemoradio-therapy is suitable for elderly patients. The study by Semrau et al found that elderly patients with NSCLC can tolerate concurrent chemoradiotherapy.[@b52-tcrm-14-2213],[@b53-tcrm-14-2213]

In recent years, no notable progress has been made with respect to LA-NSCLC treatment, so new treatment strategies are urgently needed. In 2017, a randomized controlled clinical trial published in *The New England Journal of Medicine* showed durvalumab can reverse PD-1-mediated inhibitory signals, enhance the function of effector T-cells, and restore the cytotoxic effects of T-cells against cancer cells. Efficacy was demonstrated by the extension of progression-free survival.[@b54-tcrm-14-2213]

The present study has two important limitations. First, the retrospective design is associated with known risks of bias, and a prospective randomized controlled trial is needed to confirm that VATS is safe and effective for elderly patients with LA-NSCLC. Second, we examined data from a single center only, and it is possible that our findings may not generalize to other centers and/or patient groups.

In conclusion, our study suggests that VATS does not increase the incidence of postoperative complications in elderly patients with LA-NSCLC and that these patients may achieve long-term outcomes similar to 55--69 years patients. Thus, age is not a contraindication for elderly patients with LA-NSCLC to undergo VATS treatment.
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###### 

Comparison of baseline characteristics of the two groups

  Characteristics            ≥70 years (n=37)   55--69 years (n=46)   *P*-value
  -------------------------- ------------------ --------------------- -----------
  Age (years)                73 (70--76)        64 (55--69)           0.000
  Gender (Male: female)      23: 14             28: 18                0.904
  SCS                                                                 0.509
   ≥9                        22                 24                    
   \<9                       15                 22                    
  Neoadjuvant therapy        5                  8                     0.629
   Gemcitabine + Cisplatin   4                  6                     
   Docetaxel + Carboplatin   4                  2                     
  Clinical TNM stage                                                  0.551
   IIA                       19                 21                    
   IIB                       11                 14                    
   IIIA                      7                  11                    
  ASA score                                                           0.687
   I                         19                 23                    
   II                        12                 21                    
   III                       6                  2                     
  Tumor location                                                      
   Left upper lobe           11                 13                    0.883
   Left lower lobe           7                  8                     0.857
   Right upper lobe          11                 14                    0.945
   Right middle lobe         3                  4                     1.000
   Right lower lobe          5                  7                     0.826

**Abbreviations:** ASA, American Society of Anesthesiologists; SCS, simplified comorbidity score; TNM, tumor/node/metastasis.

###### 

Comparison of surgical outcomes of the two groups

  Outcomes                                           ≥70 years (n=37)   55--69 years (n=46)   *P*-value
  -------------------------------------------------- ------------------ --------------------- -----------
                                                                                              
  Conversion                                         3                  4                     0.243
  Cause of conversion                                                                         
   Bleeding                                          2                  3                     
   Adhesion                                          1                  0                     
   Tumor extension                                   0                  1                     
  Blood loss (mL)                                    180 (160--300)     170 (150--280)        0.187
  Surgical duration (minutes)                        200 (170--250)     190 (150--260)        0.254
  Tube duration (days)                               7 (4--11)          6 (5--8)              0.210
  Postoperative hospital stay (days)                 10 (7--28)         9 (7--21)             0.301
  Patients with postoperative 30-day complications   8                  9                     0.818
   Prolonged air leak (\> 5 days)                    4                  5                     
   Pneumonia                                         2                  3                     
   Chylothorax                                       2                  1                     
   Respiratory insufficiency                         1                  2                     
   Acute heart failure                               1                  1                     
   Atrial fibrillation                               1                  0                     
  Patients with major complications                  2                  1                     0.847
  Postoperative 30-day mortality                     0                  0                     --

###### 

Comparison of pathological outcomes of the two groups

  Outcomes                   ≥70 years (n=37)   55--69 years (n=46)   *P*-value
  -------------------------- ------------------ --------------------- -----------
                                                                      
  Histological type                                                   0.964
   Adenocarcinoma            29                 35                    
   Squamous cell carcinoma   6                  8                     
   Large cell carcinoma      2                  3                     
  Pathological stage                                                  0.707
   IIA                       11                 15                    
   IIB                       10                 13                    
   IIIA                      16                 18                    
  Residual tumor                                                      1.000
   R0                        37                 46                    
   R1                        0                  0                     
   R2                        0                  0                     

**Notes:** R0: macroscopically and microscopically complete resection. R1: microscopically positive margins. R2: macroscopic residual tumor.

###### 

Comparison of chemotherapy compliance of the two groups

  Outcomes                                        ≥70 years (n=37)   55--69 years (n=46)   *P*-value
  ----------------------------------------------- ------------------ --------------------- -----------
                                                                                           
  Patients with at least one cycle chemotherapy   29                 36                    0.990
  Adjuvant chemotherapy regimens                                                           0.248
   Gemcitabine + Cisplatin                        21                 29                    
   Paclitaxel + Carboplatin                       5                  3                     
   Vinorelbine + Cisplatin                        3                  4                     
  Time to first chemotherapy (months)             6 (5--9)           6 (4--8)              0.504
  Received full dose on schedule (n)              22                 31                    0.455
  Cycles completed                                3 (1--5)           4 (2--6)              0.219

###### 

Comparison of follow-up data of the two groups

  Outcomes                                           ≥70 years (n=37)   55--69 years (n=46)   *P*-value
  -------------------------------------------------- ------------------ --------------------- -----------
                                                                                              
  Mortality                                          9                  11                    0.965
   Died of cancer recurrence                         8                  10                    
   Died of nononcological causes                     1                  1                     
  Overall recurrence                                 10                 14                    0.734
   Locoregional recurrence                           3                  4                     
   Distant recurrence                                5                  7                     
   Concurrent recurrence                             2                  3                     
  Time to first cancer recurrence (median, months)   18 (8--40)         15 (8--37)            0.309

###### 

Univariate and multivariate analyses for predictive factors of overall survival

  Factors     Univariate Favorable vs unfavorable   *P*-value   OR      Multivariate 95% CI   *P*-value
  ----------- ------------------------------------- ----------- ------- --------------------- -----------
                                                                                              
  Age         \<70 vs ≥70 years                     0.570       --      --                    --
  Sex         Male vs female                        0.128       --      --                    --
  SCS score   \<9 vs ≥9                             0.024       1.547   1.257--1.987          0.038
  T stage     T1--T2 vs ≥ T3--T4                    0.011       2.240   1.470--3.021          0.018
  N stage     N0--N1 vs ≥ N2                        0.040       2.048   1.540--2.350          0.031

**Abbreviation:** SCS, simplified comorbidity score.

###### 

Univariate and multivariate analyses for predictive factors of disease-free survival

  Factors     Univariate Favorable vs unfavorable   *P*-value   OR      Multivariate 95% CI   *P*-value
  ----------- ------------------------------------- ----------- ------- --------------------- -----------
                                                                                              
  Age         \<70 vs ≥70 years                     0.831       --      --                    --
  Sex         Male vs female                        0.079       1.281   0.458--1.450          0.324
  SCS score   I--II vs ≥ III                        0.018       1.348   1.218--1.789          0.044
  T stage     T1--T2 vs ≥ T3--T4                    0.038       2.017   1.558--3.257          0.027
  N stage     N0--N1 vs ≥ N2                        0.028       2.014   1.320--2.870          0.030

**Abbreviation:** SCS, simplified comorbidity score.
